Potential Negative Consequences of Tying ADHD Too Closely to Medication Solutions
Attention-Deficit/Hyperactivity Disorder (ADHD) has seen an uptick in diagnoses over the past few decades. This increase has coincided with a greater awareness of the disorder, advancements in diagnostic methods, and the commercial availability of pharmaceutical treatments. Among these developments, the role of pharmaceutical solutions has been particularly pronounced, raising concerns about the potential negative consequences of tying ADHD too closely to medication solutions.
📚 Get your copy today and become an informed advocate: Big Pharma Says You Have ADHD! or on Amazon.com.
One of the primary concerns is that the pharmaceutical industry has an inherent interest in maximizing the number of individuals who are prescribed their products. Schwartz and Cohen (2009) argue that there’s a risk in the overdiagnosis and overtreatment of ADHD in societies where pharmaceutical solutions are heavily promoted. Overdiagnosis can lead to individuals without the disorder being subjected to unnecessary medical interventions.
This concern is not isolated to ADHD. In her seminal work, “The Truth About the Drug Companies,” Dr. Marcia Angell, a former editor-in-chief of The New England Journal of Medicine, highlights the ways in which pharmaceutical companies might…
